TransMedics price target raised to $200 from $125 at Oppenheimer

Oppenheimer analyst Suraj Kalia raised the firm’s price target on TransMedics to $200 from $125 and keeps an Outperform rating on the shares. The firm notes TransMedics reported Q2 revenues of $114.3M, blowing past its/consensus $100.2M/$98.8M estimates. Oppenheimer highlights that aviation business is complementary to overall organ share gains; new product iterations is tantalizing; and OpEx leverage and organ share gains are occurring faster than expected.